Apyx Medical (APYX) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Apyx Medical (APYX) has outperformed Sera Prognostics (SERA) over the past year, losing 17.8% versus a loss of 35.9%. Over five years, SERA leads with a -81.4% price change compared with -82.1% for APYX. Apyx Medical is the larger company by market cap ($99.4 million vs $79.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APYX | SERA |
|---|---|---|
| Share price | $2.36 | $2.02 |
| Market cap | $99.41M | $79.69M |
| 1-day change | -7.45% | -2.42% |
| YTD return | -32.57% | -31.53% |
| 1-year return | -17.77% | -35.87% |
| 5-year return | -82.05% | -81.38% |
| EPS (TTM) | $-0.20 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.08 | $3.95 |
| 52-week low | $2.32 | $1.56 |
| Distance from 52-week high | -53.54% | -48.86% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +175.42% | +172.28% |
| Average volume | 127.72K | 28.38K |
| Shares outstanding | 42.12M | 38.48M |
| Employees | 205 | 71 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- APYX has outperformed SERA by 18.1 percentage points over the past year.
About Apyx Medical
APYX stock →Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM).
Healthcare · Medical Devices · 205 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Healthcare · Medical Devices · 71 employees
APYX vs SERA FAQ
Which is bigger, Apyx Medical or Sera Prognostics?
Apyx Medical (APYX) is larger, with a market capitalization of $99.41M compared with $79.69M for Sera Prognostics (SERA).
Which stock has performed better over the past year, APYX or SERA?
APYX returned -17.77% over the past 12 months, compared with -35.87% for SERA (price return, excluding dividends). Past performance does not predict future results.
Are Apyx Medical and Sera Prognostics in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.